Central & South Asia
India ruling on cancer drug to be challenged
Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.
Last Modified: 15 Mar 2012 04:50

A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

Prerna Suri reports from New Delhi.

Al Jazeera
Topics in this article
Featured on Al Jazeera
UNHCR says hundreds of people trapped in Yaloke town risk death if they are not evacuated to safety urgently.
'Justice for All' demonstrations swell across the US over the deaths of African Americans in police encounters.
Six former Guantanamo detainees are now free in Uruguay with some hailing the decision to grant them asylum.
Disproportionately high number of Aboriginal people in prison highlights inequality and marginalisation, critics say.
Long-standing dispute over Christian use of the word 'Allah' raises concerns about a very un-Merry Christmas.
The threat posed by ISIL has prompted thousands of young Kurds to join the PKK.
Baja California - with its own grim history of disappeared people - finds a voice in the fight against violence.
Russian feminist rockers fight system holding 700,000 - the world's largest per capita prison population after the US.
Weeks of growing protests against Muslims continue in Dresden with 15,000 hitting the streets last Monday.